Agenda
The Live Virtual Experience will include top experts sharing highlights from over 25 on-demand presentations*, available 9 September 2021. The on-demand presentations will be available through the virtual platform. These interactive panel discussions will also feature debates and Q&A from the live audience.
Friday 17 September 2021
Day 1
| 9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins | Opening Remarks | Tadeusz Robak, MD, PhD |
| Theme 1: Pathogenesis of CLL | |||
| 9:05 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Session 1: Molecular Pathogenesis of CLL – Genomics and Proteomics |
Co-Chairs: Catherine J. Wu, MD & Clare Sun, MD |
Genomic Analysis of CLL |
Anna Schuh, MD, PhD | ||
| Novel Insights From Proteogenomic Analysis |
Michael Gillette, MD, PhD | ||
| 9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Genomic Analysis of CLL & *Novel Insights From Proteogenomic Analysis  |
Catherine J. Wu, MD; Clare Sun, MD; Anna Schuh, MD, PhD; Michael Gillette, MD, PhD |
| 9:40 AM (EDT) 15:40 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 9:50 AM (EDT) 15:50 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 10:00 AM (EDT) 16:00 (GMT +2) (CEST) |
10 mins | Visit Exhibit Hall & Break | |
| 10:05 AM (EDT) 16:05 (GMT +2) (CEST) |
5 mins | Session 2: Molecular Pathogenesis of CLL – Microenvironment & Signaling | Co-Chairs: Nicholas Chiorazzi, MD & Sarka Pospisilova, PhD |
| Trafficking of Leukemic and Normal Cellular Elements to/from Microenvironmental Niches |
Andrea Buggins Pepper, PhD | ||
| Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells |
Dimitar Efremov, MD, PhD | ||
| Crosstalk of Microenvironmental Elements in the Tissue Microenvironment |
Alan Ramsay, PhD | ||
| 10:10 AM (EDT) 16:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Trafficking of Leukemic and Normal Cellular Elements to/from Microenvironment Niches *Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells *Crosstalk of MIcroenvironment Elements in the Tissue Microenvironment |
Nicholas Chiorazzi, MD; Sarka Pospisilova, PhD; Andrea Buggins Pepper, PhD; Dimitar Efremov, MD, PhD; Alan Ramsay, PhD |
| 10:40 AM (EDT) 16:40 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 10:50 AM (EDT) 16:50 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 11:00 AM (EDT) 17:00 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 11:05 AM (EDT) 17:05 (GMT +2) (CEST) |
5 mins | Session 3: Clonal Dynamics, Competition, and Disease Evolution |
Co-Chairs: Gianluca Gaidano, MD, PhD & Adalgisa Condoluci, MD |
| Mechanisms of Epigenetic Dynamics/Evolution |
Davide Rossi, MD, PhD | ||
| Perspectives of Clonal Evolution at the Single Cell Level |
Catherine J. Wu, MD | ||
| 11:10 AM (EDT) 17:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Mechanisms of Epigenetic Dynamics/Evolution *Perspectives of Clonal Evolution at the Single Cell Level |
Gianluca Gaidano, MD, PhD; Adalgisa Condoluci, MD; Davide Rossi, MD, PhD; Catherine J. Wu, MD |
| 11:40 AM (EDT) 17:40 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 11:50 AM (EDT) 17:50 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 12:00 PM (EDT) 18:00 (GMT +2) (CEST) |
End of Day 1 | ||
| 12:00 PM (EDT) 18:00 (GMT +2) (CEST) |
60 mins | Poster Session | |
| 1:00 PM (EDT) 19:00 (GMT +2) (CEST) |
Poster Session Concludes |
Saturday 18 September 2021
Day 2
| Theme 2: Approach Considerations and Treatment Options in CLL | |||
| 9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins | Opening Remarks & Recap of Previous Day | |
| 9:05 AM (EDT) 15:10 (GMT +2) (CEST) |
5 mins | Session 4: Prognostication and Prediction in the Era of Novel Drugs |
Chair: Peter Hillmen, MB ChB, PhD |
| The Use of Conventional Prognostic Markers with Targeted Therapy |
Eugen Tausch, MD | ||
| Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era |
Romain Guièze, MD | ||
| 9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
45 mins | Panel Discussion featuring highlights from the following on-demand presentations: *The Use of Conventional Prognostic Markers with Targeted Therapy *Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era |
Peter Hillmen, MB ChB, PhD; Eugen Tausch, MD; Romain Guièze, MD |
| 9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
45 mins | Debate | Debate: In the Era of Novel Agents – Do Prognostic/Predictive Markers Matter? |
| 9:55 AM (EDT) 15:55 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 10:05 AM (EDT) 16:05 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 10:15AM (EDT) 16:15 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 10:20 AM (EDT) 16:20 (GMT +2) (CEST) |
5 mins | Session 5: Minimal Residual Disease – Methods and Clinical Application | Co-Chairs: Thomas Kipps, MD, PhD & Kirsten Fischer, MD |
| Minimal Residual Disease |
William Wierda, MD, PhD | ||
| 10:25 AM (EDT) 16:25 (GMT +2) (CEST) |
45 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Minimal Residual Disease |
Thomas Kipps, MD, PhD; Kirsten Fischer, MD; William Wierda, MD, PhD |
| Debate | Debate: Can we design an acceptable uMRD-treatment endpoint clinical trial which can direct standard practice for first-line and R/R CLL? | ||
| 11:10 AM (EDT) 17:10 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 11:10 AM (EDT) 17:10 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 11:30 AM (EDT) 17:30 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 11:35 AM (EDT) 17:35 (GMT +2) (CEST) |
60 mins | Industry Supported Satellite Symposia | |
| 12:35 PM (EDT) 18:35 (GMT +2) (CEST) |
10 mins | Binet/Rai Medal Presentation | |
| 12:45 PM (EDT) 18:45 (GMT +2) (CEST) |
5 mins | Session 6: Front-Line Therapy of CLL | Co-Chairs: Barbara Eichhorst, MD & Lydia Scarfo, MD |
| Relevant Factors for Choice of Frontline Therapy |
Arnon Kater, MD, PhD | ||
| Treatment of Very High Risk CLL (TP53, Complex Karyotype; IGHV Subset 2) |
Inhye Ahn, MD | ||
| Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances? |
Matthew Davids, MD, MMSc | ||
| 12:50 PM (EDT) 18:50 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Relevant Factors for Choice of Frontline Therapy *Treatment of Very High Risk CLL (TP53, Complex Karyotype; IGHV Subset 2) *Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances? |
Barbara Eichhorst, Lydia Scarfo, MD; MD; Arnon Kater, MD, PhD; Inhye Ahn, MD; Matthew Davids, MD, MMSc |
| 12:50 PM (EDT) 18:50 (GMT +2) (CEST) |
30 mins | Highlights of Presentations & Panel Discussion | Barbara Eichhorst, MD; Arnon Kater, MD, PhD; Inhye Ahn, MD; Matthew Davids, MD, MMSc |
| 1:20 PM (EDT) 19:20 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 1:30 PM (EDT) 19:30 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 1:40 PM (EDT) 19:40 (GMT +2) (CEST) |
End of Day 2 | ||
| 1:40 PM (EDT) 19:40 (GMT +2) (CEST) |
60 mins | Poster Session | |
| 2:40 PM (EDT) 20:40 (GMT +2) (CEST) |
Poster Session Concludes |
Sunday 19 September 2021
Day 3
| 9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins | Opening Remarks & Recap of Previous Day | |
| 9:05 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Session 7: Treatment of Relapsed/Refractory CLL | Co-Chairs: John Seymour, MD & Meghan Thompson, MD |
| Resistance to Venetoclax: Mechanisms, Risk Factors and Preventative Strategies |
Andrew Roberts, MBBS, PhD | ||
| A Clinical Perspective on Resistance to Covalent BTKi |
Jennifer Woyach, MD | ||
| Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for Each Patient |
Richard Rosenquist, MD, PhD | ||
| 9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Resistance to Venetoclax: Mechanisms, Risk Factors, and Preventative Strategies *A Clinical Perspective on Resistance to Covalent BTKi *Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for EAch Patient |
John Seymour, MD; Meghan Thompson, MD; Andrew Roberts, MBBS, PhD; Jennifer Woyach, MD; Richard Rosenquist, MD, PhD |
| 9:40 AM (EDT) 15:40 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 9:50 AM (EDT) 15:50 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 10:05AM (EDT) 16:05 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| Theme 3: Rationally Designed Therapy on the Horizon in CLL |
|||
| 10:05 AM (EDT) 16:05 (GMT +2) (CEST) |
5 mins | Session 8: New Agents in CLL Clinical Trials | Co-Chairs: Jennifer Woyach, MD & Lindsey Roeker, MD |
| 10:05 AM (EDT) 16:05 (GMT +2) (CEST) |
5 mins | Refining our Standard Approaches |
Paolo Ghia, MD, PhD |
| Reversible BTK Inhibitors |
Jennifer Brown, MD, PhD | ||
| Preclinical Methods for Drug Discovery |
Rosa Lapalombella, PhD | ||
| 10:10 AM (EDT) 16:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Refining our Standard Approaches *Reversible BTK Inhibitors *Preclinical Methods for Drug Discovery |
Jennifer Woyach, MD; Lindsey Roeker, MD; Paolo Ghia, MD, PhD; Jennifer Brown, MD, PhD; Rosa Lapalombella, PhD |
| 10:40 AM (EDT) 16:40 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 10:50 AM (EDT) 16:50 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 11:00 AM (EDT) 17:00 (GMT +2) (CEST) |
60 mins | Industry Supported Satellite Symposia | |
| 12:00 AM (EDT) 18:00 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 12:05 PM (EDT) 18:05 (GMT +2) (CEST) |
5 mins | Session 9: Immunotherapy of CLL | Co-Chairs: John Gribben, MD, DSc & David Maloney, MD, PhD |
| 12:10 PM (EDT) 18:10 (GMT +2) (CEST) |
5 mins | Debate – CAR T-cell Therapy vs Allo-SCT |
Moderators: John Gribben, MD, DSc; Jordan Gauthier MD, MSc; Peter Dreger, MD |
| Novel Immunologic Approaches |
Jan Burger, MD, PhD | ||
| Bispecific Monoclonal Antibodies |
Adrian Wiestner, MD, PhD | ||
| 12:40 PM (EDT) 18:40 (GMT +2) (CEST) |
5 mins | Panel Discussion (live icon) featuring the following on-demand presentations: *Novel Immunologic Approaches *Bispecific Monoclonal Antibodies |
John Gribben, MD, DSc David Maloney, MD, PhD Jan Burger, MD, PhD Adrian Wiestner, MD, PhD Jordan Gauthier MD, MSc Peter Dreger, MD |
| 1:10 PM (EDT) 19:10 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 1:20 PM (EDT) 19:20 (GMT +2) (CEST) |
10 mins | Oral Abstract | |
| 1:30 PM (EDT) 19:30 (GMT +2) (CEST) |
End of Day 3 | ||
| 1:30 PM (EDT) 19:30 (GMT +2) (CEST) |
60 mins | Poster Session | |
| 2:30 PM (EDT) 20:30 (GMT +2) (CEST) |
Poster Session Concludes |
Monday 20 September 2021
Day 4
| 9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins | Opening Remarks & Recap of Previous Day | |
| 9:05 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Session 10: Supportive Care and Consequences of Immune Dysregulation in CLL |
Co-Chairs: Jennifer Brown, MD, PhD & Jackie Barrientos, MD |
| Infection Risk in CLL |
Carsten Niemann, MD, PhD |
||
| Infection Risk with Novel Agents |
Florence Cymbalista, MD, PhD |
||
| Management of Autoimmune Cytopenias in the Era of Targeted Agents |
Kerry Rogers, MD |
||
| COVID-19 and CLL |
Lydia Scarfò, MD |
||
| Management of Cardiac Complications of BTK Inhibitors |
Javid Moslehi, MD |
||
| 9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
45 mins | Panel Discussion featuring the following on-demand presentations: *Infection Risk in CLL *Infection Risk with Novel Agents *Management of Autoimmune Cytopenias in the Era of Targeted Agents *COVID-19 and CLL *Management of Cardiac Complications of BTK Inhibitors |
Jennifer Brown, MD, PhD; Jackie Barrientos, MD; Carsten Niemann, MD, PhD; Florence Cymbalista, MD, PhD; Kerry Rogers, MD; Lydia Scarfò, MD; Javid Moslehi, MD |
| 9:55 AM (EDT) 15:55 (GMT +2) (CEST) |
60 mins | Industry Supported Satellite Symposia | |
| Visit Exhibit Hall & Break | |||
| Theme 4: From Global Perspectives to Patient Experiences – How iwCLL Is Leading the Way | |||
| 11:00 AM (EDT) 17:00 (GMT +2) (CEST) |
5 mins | Session 11: Real-World Data and Patient Experiences | Co-chairs: Peter Hillmen, MB ChB, PhD; John Seymour, MD |
| 11:05 AM (EDT) 17:10 (GMT +2) (CEST) |
10 mins | Global Committee for iwCLL |
Anna Schuh, MD, PhD |
| 11:15 AM (EDT) 17:15 (GMT +2) (CEST) |
7 mins | ERIC Updates |
Paolo Ghia, MD, PhD |
| 11:22 AM (EDT) 17:22 (GMT +2) (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in China |
Shenmiao Yang, MD |
| 11:29 AM (EDT) 17:29 (GMT +2) (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in South America |
Carlos Sergio Chiattone, MD, MSc, PhD |
| 11:36 AM (EDT) 17:36 (GMT +2) (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in Africa |
Clara Chamba, MD |
| 11:43 AM (EDT) 17:43 (GMT +2) (CEST) |
5 mins | Oral Abstract | |
| 11:48 AM (EDT) 17:48 (GMT +2) (CEST) |
5 mins | Oral Abstract | |
| 11:53 AM (EDT) 17:53 (GMT +2) (CEST) |
15 mins | Real-World Data Roundtable Discussion |
Peter Hillmen, MB ChB, PhD Anna Schuh, MD Paolo Ghia, MD, PhD Shenmiao Yang, MD Carlos Sergio Chiattone, MD, MSc, PhD Clara Chamba, MD |
| 12:08 AM (EDT) 18:08 (GMT +2) (CEST) |
7 mins | Visit Exhibit Hall & Break | |
| 12:15 PM (EDT) 18:15 (GMT +2) (CEST) |
45 mins | Live Panel Discussion: Spotlight on the CLL Patient Experience: Perspectives Learned From Three Datasets & Patient Experience/Perspective/Solutions |
John Seymour, MD Deb Henderson (Sims) Dr. Brian Koffman, CMO and EVP, CLL Society Lorna Warwick, CEO, Lymphoma Coalition Zack Pemberton-Whiteley, CEO, Leukaemia Care |
| 1:00 PM (EDT) 19:00 (GMT +2) (CEST) |
5 mins | Session 12: Looking to the Future of CLL and iwCLL | Michael Hallek, MD, PhD; Peter Hillmen, MB ChB, PhD |
| 1:05 PM (EDT) 19:05 (GMT +2) (CEST) |
30 mins | Keynote: Advances in CLL: Is It Time to Talk Cure |
Michael Hallek, MD, PhD |
| 1:35 PM (EDT) 19:35 (GMT +2) (CEST) |
15 mins | iwCLL Updates and iwCLL 2023 | Peter Hillmen, MB ChB, PhD; Jennifer Brown, MD, PhD |
| 1:50 PM (EDT) 19:50 (GMT +2) (CEST) |
5 mins | Closing Comments | Michael Hallek, MD, PhD |
| 1:55 PM (EDT) 19:55 (GMT +2) (CEST) |
Close of Workshop |